Plain-English translation of NCT07360080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This study is following up with people who received , a medication designed to slow down type 1 diabetes in its earliest stages. Researchers want to understand how well this treatment works over many years and what health outcomes people experience after receiving it. By tracking participants for up to 10 years, the study aims to answer important questions about whether catching and treating diabetes early can make a real difference in people's lives.
Type 1 diabetes develops gradually, and treating it very early—before symptoms appear—may help preserve the body's ability to produce insulin. This study exists to understand whether this medication truly helps people in the long run and how it affects their diabetes progression and overall health over time.
You likely qualify if…
You likely don't qualify if…
As a participant, you would be part of a long-term follow-up study where researchers track your health outcomes over the next several years (up to 10 years, depending on when you started the medication). This means periodic visits to your doctor to check your blood sugar levels, diabetes progression, and overall health. You are not receiving the medication as part of this study—you've already received it in routine care—but researchers will monitor how well it has worked for you over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Israel